Investigational drug · Phase 2
LBL-034
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed/Refractory Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "LBL-034"
First trial start
2023
Oct 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LBL-034", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "LBL-034" as an intervention, largest first.
Nanjing Leads Biolabs Co.,LtdIndustry
NCT06049290 · 342 participants (planned) · Start Oct 20, 2023 · Primary completion Sep 20, 2029
Drug: LBL-034 for Injection · For: Relapsed/Refractory Multiple Myeloma
Sites: Wuhu, China; Beijing, China; Xiamen, China · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed/Refractory Multiple Myeloma
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- SG301Phase 33 trials
Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection
- BCD-248Phase 32 trials
Biocad · Relapsed/Refractory Multiple Myeloma, Myeloma Multiple
- Eque-celFully Human BCMA Chimeric Antigen Receptor Autologous T CellPhase 21 trial
Nanjing IASO Biotechnology Co., Ltd. · Relapsed/Refractory Multiple Myeloma
- REGN7945Phase 21 trial
Regeneron · Relapsed/Refractory Multiple Myeloma
- SG2918Phase 21 trial
Hangzhou Sumgen Biotech Co., Ltd. · Relapsed/Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.